Although members of SOX family have been well documented for their essential roles in embryonic development, cell proliferation and disease, the functional role and molecular mechanism of SOX30 in cancer are largely unexplored. Here, we first identified SRYbox containing gene 30 (SOX30) as a novel preferentially methylated gene using genome-wide methylation screening. SOX30 hypermethylation was detected in 100% of lung cancer cell lines (9/9) and 70.83% (85/120) of primary lung tumor tissues compared with none (0/20) of normal and 8.0% (2/25) of peri-tumoral lung tissues (P o0.01). SOX30 was expressed in normal and peri-tumoral lung tissues in which SOX30 was unmethylated, but was silenced or downregulated in lung cancer cell lines and primary lung tumor tissues harboring a hypermethylated SOX30. De-methylation experiments further confirmed that silence of SOX30 was regulated by its hypermethylation. Ectopic expression of SOX30 induces cancer cell apoptosis with inhibiting proliferation in vitro and represses tumor formation in vivo, whereas knockdown of SOX30 demonstrates a reversed effect both in vitro and in vivo. At the molecular level, the antitumorigenic effect of SOX30 is mediated by directly binding to CACTTTG (+115 to +121) of p53 promoter region and activating p53 transcription, suggesting that SOX30 is a novel transcriptional activating factor of p53. Indeed, blockade of p53 attenuates the tumor inhibition of SOX30. Overall, these findings demonstrate that SOX30 is a novel epigenetic silenced tumor suppressor acting through direct regulation of p53 transcription and expression. This study provides novel insights on the mechanism of tumorigenesis in lung cancer.
INTRODUCTION
Lung cancer is the most commonly diagnosed cancer, as well as the leading cause of cancer death in males and among females, it is the fourth most frequent cancer and the second leading cause of cancer death in 2008 globally. 1, 2 It represents the most common malignancy and is rapidly increasing in China. Carcinogenesis is a complex multistep process presenting a variety of genetic and epigenetic abnormalities. Aberrant epigenetic changes are one of the most frequent events and are regarded as important mechanisms in carcinogenesis. 3, 4 Moreover, methylation profiles have been used as potential biomarkers for early diagnosis, prognosis and screening in some cancers. 5 Recently, accumulating evidence demonstrated that DNA hypermethylation of tumor-suppressor genes (TSGs) associated with gene silencing has an essential role in carcinogenesis. [6] [7] [8] [9] [10] Increasing numbers of TSGs associated with epigenetic alterations have been identified in human cancers. 9, [11] [12] [13] The identification of new useful biomarkers and new genes functionally involved in tumor development may provide alternative approaches for diagnostic and prognostic evaluation.
Through methylation-sensitive representational difference analysis, we have identified a novel preferentially methylated gene, SRY-box containing gene 30 (SOX30), in human lung cancer. SOX family members contain a highly conserved high mobility group (HMG) DNA-binding domain, 14 and have critical roles in the regulation of cell fate and differentiation during embryonic and postnatal development. 15 So far, SOX30 has been characterized in only a few species. It was first cloned from mouse and human. 16 Recently, Sox30 was isolated from the Nile tilapia accidentally and was indicated to exist widely throughout the animal kingdom in our previous studies. 17 In mouse and human, Sox30 is considered to be involved in mammalian spermatogonial differentiation and spermatogenesis. 16, 18 In the Nile tilapia, Sox30 may be involved in female and male gonadal development. 17 However, it remains unclear whether SOX30 has any role in cancer.
In this study, we observed a frequent loss of SOX30 expression because of DNA hypermethylation in human lung cancers. Gainand loss-of-function studies demonstrated that SOX30 induced apoptosis with inhibiting proliferation of lung cancer cell lines in vitro, and repressed tumor growth in vivo. Further, SOX30 directly activated p53 transcription and expression, which mediated its function as a tumor suppressor.
RESULTS

SOX30
is hypermethylated in lung cancer cell lines and lung cancers To screen for differentially methylated DNA fragments and potential cancer-related genes with methylation, we used genome-wide methylation screening and identified a novel preferentially methylated gene SOX30 in lung cancer. Pairs of primers for methylation-specific polymerase chain reaction (MSP) and bisulfite genomic sequencing (BGS) were designed ( Figure 1a ). The MSP analysis showed that SOX30 was hypermethylated in lung cancer cell lines and a substantial proportion of cancer cases (Figures 1b and c) . In contrast, SOX30 of non-tumor lung tissues exhibited an unmethylated status (Figures 1b and c) . The MSP results were further validated by BGS analysis of SOX30 isolated from A549, H460, H358, T8 and N6 cell lines or tissue samples (Figures 1d and e) .
In total, we examined SOX30 methylation in 20 normal lung samples, 25 adjacent controls, 120 tumors and 9 lung cancer cell lines by MSP. The methylation incidence of SOX30 was 0% (0/20), 8% (2/25), 70.83% (85/120) and 100% (9/9) in these samples, respectively (Supplementary Table S2 ). The frequency of SOX30 methylation was lower in normal lung tissues from the control subjects than in lung cancer tissues from patients (0/20 (0%) vs 85/120 (70.83%); P o 0.001), and it did not differ in adjacent tissues of cancer patients from normal lung tissues (2/25 (8%) vs 0/20 (0%); P = 0.495) ( Supplementary Table S2 ). When analyzing the relationship between SOX30 methylation status and clinical characteristics of these patients (after exclusing those with incomplete clinicopathological features, a total of 84 cases were analyzed), we did not find significant association of SOX30 methylation status with gender, age, grade, tumor size or tumor types (Supplementary Table S3 ).
Methylation of SOX30 is correlated with its transcriptional silencing To determine the relationship between hypermethylation and expression of SOX30, a correlation analysis was performed on cell lines and pairs of primary tumor vs non-tumor tissues by reverse transcription-polymerase chain reaction (RT-PCR), quantitative RT-PCR (qRT-PCR), western blot (WB) and immunohistochemistry. The results showed that SOX30 was silenced or downregulated in cancer cell lines and tumor samples with hypermethylated SOX30 (Figures 2a and b, Supplementary Figure S1A ). In contrast, SOX30 could be broadly detected in normal lung tissues in which SOX30 is unmethylated (Figure 2b, Supplementary Figure S1A ). The expression of SOX30 was lower in lung tumors than that in adjacent non-tumor and normal lung tissues (Figure 2c , Supplementary Figures S1A-C) , suggesting an aberrant gene silencing of SOX30 in lung cancer. These results indicate that silencing of SOX30 in tumors may be due to hypermethylation of SOX30. To test this hypothesis, we treated cell lines with 5-aza-2′-deoxycytidine, a pharmacological inhibitor of DNA methylation, which restored the expression of the silenced SOX30 in those cell lines (Figure 2d, Supplementary Figures S2A and B) , suggesting that methylation is essential for silencing of SOX30. In addition, we also detected SOX30 expression levels during human lung development, and found that SOX30 was relatively highly expressed in human adult lung (Supplementary Figure S2C) .
Genetic deletion and mutation of SOX30 is not detected in lung cancer We next determined genetic deletion and mutation of SOX30 coding exons and promoter by DNA direct sequencing. We did not observe any homozygous deletion or mutation of SOX30 in three cancer cell lines (A549, H460 and H1975) and five primary cancers (chosen randomly), suggesting that genetic alteration does not contribute to the silencing of SOX30 in lung cancer (data not shown).
SOX30 overexpression inhibits proliferation and promotes apoptosis To explore the potential role of SOX30 in tumorigenesis, we first generated gain-of-function cell models by transfecting a SOX30-expressing construct into the human adenocarcinoma A549 (A549) and large cell lung cancer NCI-H460 (H460) cell lines. The expression of exogenous SOX30 was confirmed by RT-PCR and WB (Figure 3a) . We then examined the effect of SOX30 overexpression on cell proliferation and viability. Five-day growth curve analysis showed that overexpression of SOX30 inhibited proliferation of A549 and H460 cells (Figure 3b ). The suppressive effect of SOX30 on cell proliferation was confirmed by colony formation and EdU assays. SOX30-expressing A549 and H460 (SOX30) formed about 20 and 40% colonies of their controls (Vector), respectively (Po0.01) (Figures 3c and d) . SOX30 overexpression decreased the number of EdU + cells in both A549 and H460 cell lines (Figure 3e ). To examine the effect of SOX30 overexpression on cell viability, we measured the percentage of sub-G1 phase cells, and conducted Annexin V-APC/7-amino-actinomycin D double staining followed by flow cytometry analysis and DNA ladder assay. Both A549 and H460 cells transfected with SOX30 had a significant higher percentage of sub-G1 apoptotic cells as compared with Figure S4A ). These results indicated that the antitumorigenicity of SOX30 might be mediated by activation of the p53 signaling pathway.
To further determine whether p53 is the possible target gene of SOX30, the expression of SOX30 and p53 in xenograft tumors was examined by qRT-PCR and WB. The results indicated that p53 was increased markedly both at mRNA and protein levels in xenograft tumor tissues when SOX30 was expressed (Figures 6c and d, Supplementary Figure S4B ). Furthermore, we detected cell proliferation and apoptosis in vivo using xenograft tumor tissues by Ki67 and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining, respectively. The results showed that a decrease in proliferating cells and an increase in apoptotic cells were observed in SOX30-overexpressing tumors (Supplementary Figure S4C, Figure 6e ). Taken together, these data suggested that p53 was the highly possible target gene of SOX30 in lung cancer.
P53 is a direct target of SOX30 To investigate whether p53 is a direct target of SOX30, we searched the putative SOX transcription factor-binding sites in p53 promoter using Jaspar (http://jaspar.genereg.net/). Several SOX transcription factor-binding sites were identified in p53 promoter region (Figure 7a, Supplementary Figure S4D ). Regarding high similarity of the DNA-binding domains (HMG-boxes) of these SOX members and SOX30 (Supplementary Figure S4E) , we speculated SOX30, methylation, apoptosis, p53 and lung cancer F Han et al that SOX30 might regulate p53 transcription by directly binding to its promoter region. To examine this hypothesis, we first performed a luciferase reporter assay. The data showed that overexpression of SOX30 significantly enhanced the activity of p53 promoter (Figure 7b) . Then, by using chromatin immunoprecipitation (ChIP)-PCR assays, we found direct binding of SOX30 to the promoter of p53, but not PMAIP1, p21 and BAX (Figure 7c, Supplementary Figures S5A-C) . To further determined the SOX30-binding sites in the p53 promoter, different regions of the p53 promoter were analyzed by luciferase reporter assays, and the SOX30-binding site was very likely on the CACTTTG (+115 to +121) locus of the p53 promoter region using both Jaspar and ConSite (http://consite.genereg.net/cgi-bin/consite) searching (Figure 7d, Supplementary Figure S5D ). These findings demonstrated that p53 was a direct target gene of SOX30 in lung cancer cell lines.
SOX30 fails to activate p53 promoter activity when binding sites are mutated or deleted To further investigate whether SOX30 activates the p53 promoter through binding to the binding site (CACTTTG) by SOX30 HMGbox, constructs with site-directed mutagenesis of binding sites in the p53 promoter (mutations and deletions) and SOX30 HMG-box (deletions) were generated. When the SOX30-binding sites in the p53 promoter were mutated (CACTTTG, bold indicates mutated) or deleted (CACTTTG, bold indicates deleted), the stimulating effect was ablated (Figure 7e) . Furthermore, the data of sitedirected mutagenesis (deletion) of SOX30 HMG-box showed that SOX30 HMG-box was required for stimulating p53 promoter activity (Figure 7f ).
Ablation of p53 attenuates the effects of SOX30 To define whether p53 was required for the antitumorigenesis function of SOX30, we blocked p53 activity or its signaling pathway by using the inhibitor pifithrin-α, or p53 small interfering RNA when overexpression of SOX30 (Figures 8a and b,  Supplementary Figure S6A ). Blockade of p53 or its signaling pathway by pifithrin-α or small interfering RNA significantly (P o 0.01) diminished the effect of SOX30 overexpression on cell proliferation and apoptosis (Figures 8c-e, Supplementary  Figure S6B ). Besides, in order to avoid the off-target effects of the small interfering RNA for p53, we evaluated SOX30-positive regulatory role on p53's expression and functions in wild-type and p53-knockout HCT116 cells. The data indicated that it had a higher percentage of apoptosis in SOX30 overexpression wild-type HCT116 cells than p53-knockout HCT116 cells Figures S6C-E) . These data indicated that p53 was required for the function of SOX30 as a tumor suppressor in lung cancer cells.
DISCUSSION
In this study, we identified SOX30 as a novel preferentially methylated gene in human lung cancer, and it is frequently silenced or downregulated in lung cancer cell lines and lung cancer samples, but is expressed in human normal and peri-tumoral lung tissues. The data suggest that the silencing or downregulation of SOX30 is closely related with its hypermethylation, as demonstrated by MSP and confirmed by BGS. De-methylation treatment with the de-methylating reagent 5-aza-2′-deoxycytidine restores the expression of SOX30 in silenced cancer cell lines, and mutation analysis showed that genetic deletion or mutation was not detected. These results indicate that hypermethylation of SOX30 mediates the transcriptional silence directly.
To investigate the clinical application of SOX30 in lung tumorigenesis in vivo, we examined the methylation of SOX30 by MSP and BGS in normal control, adjacent non-tumor and lung tumor samples. The data showed that frequent SOX30 hypermethylation occurs in lung tumor tissues, but not in normal lung or adjacent non-tumor tissues, indicating SOX30 methylation being tumor specific. These findings suggest that SOX30 methylation may be a putative epigenetic biomarker for lung cancer, which may have a high research value and application prospect.
Previous studies have considered that Sox30 may be involved in gonadal development. [16] [17] [18] In this study, SOX30 is highly methylated and frequently silenced or downregulated in human lung cancers, suggesting it may be involved in regulation lung cancer development. Ectopic expression of SOX30 in silenced lung cancer cell lines significantly induces cell apoptosis and inhibits proliferation. Conversely, knockdown of SOX30 inhibits cell apoptosis and increases proliferation. Furthermore, SOX30 significantly suppresses tumor growth in nude mice. These in vitro and in vivo studies indicate for the first time that SOX30 functions as a tumor suppressor in lung carcinogenesis.
This study improved our understanding of the molecular basis of SOX30 as a tumor suppressor. Transcriptome analysis showed that the expression of p53 and its targets, including BAX, PMAIP1 and p21, are upregulated by SOX30. Luciferase reporter and ChIP assays indicated that SOX30 directly binds to p53 promoter region, and induces its transcription and expression. Moreover, the effect of SOX30 on cancer cell proliferation and apoptosis is dependent on p53. P53 is well-known as a TSG. Induction of p53 has been reported to downregulate BCL-2 in breast cancer, 19 and SOX30, methylation, apoptosis, p53 and lung cancerupregulate BAX in lung cancer. 20 BAX is identified by its interaction with BCL-2, and it induces apoptotic cell death in response to cytokine deprivation. 21, 22 BAX is repressed by BCL-2 either directly or indirectly through titrating BH3-only proteins, and the ratio of BCL-2/BAX constitutes a rheostat that sets the threshold of susceptibility to apoptosis for the intrinsic pathway.
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PMAIP1, a 'BH3-only' member of the Bcl-2 family, was shown to be a target of p53 and/or p73-mediated trans-activation; it first translocates to mitochondria and then functions through Bax and/ or Bak to induce apoptosis. 24, 25 Recent studies demonstrated that PMAIP1 could induce apoptosis of some cancer cells. [25] [26] [27] In this study, we show that increased levels of p53 and its downstream targets, BAX and PMAIP1, are associated with overexpression of SOX30. Therefore, upregulation of p53 and its downstream targets by SOX30 could explain the effect of inducing cancer cell apoptosis with inhibiting proliferation. Blockade of p53 could reverse the effects of SOX30 overexpression, suggesting that p53 is a functionally important direct target gene of SOX30.
It has been reported that p53 can directly enhance the transcription of p21, 28, 29 which is critical for the G1 checkpoint response because p21 loss compromises p53-mediated G1 arrest in response to DNA damage. 30, 31 From our data, restoration of SOX30 increases p21 expression. However, it does not cause cell cycle arrest in G0/G1 phase (Supplementary Figure S2A) . Further studies are required to solve this discrepancy.
To define whether p53 is required for the antitumor effects of SOX30, we blocked p53 activity or its signaling pathway using the inhibitor pifithrin-α when overexpressing SOX30. Blockade of p53 signaling pathway by pifithrin-α diminished the effect of SOX30 overexpression on cell proliferation and apoptosis. In general, pifithrin-α is considered to act endogenous p53-responsive genes. However, in this study, pifithrin-α could downregulate p53 mRNA. There may be a specific mechanism whereby pifithrin-α inhibits p53 transcriptional activity. [32] [33] [34] The previous observations indicate that pifithrin-α effects are not limited to p53 and downstream components of p53 pathway but involve other cellular factors and signal transduction pathways. [35] [36] [37] Thus, whether pifithrin-α binds directly to p53 or other factors effected by pifithrin-α regulate p53 transcriptional activity is still unknown, and further study is required to clarify this.
In conclusion, we have identified a novel functional TSG SOX30 inactivated by methylation. SOX30 has important roles in inducing cell apoptosis, acting through aberrant activation of p53 by directly binding to its promoter, as well as its downstream targets 
MATERIALS AND METHODS
Cell lines and patient samples
The lung cancer cell lines (A549, H460, H1395, SPC-A-1, H1975, 95D, H358, H1650 and LTEP) were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China) and the American Type Culture Collection (ATCC, Manassas, VA, USA), cultured in RPMI-1640 (HyClone, Logan, UT, USA)/F12K (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (HyClone), and incubated in 5% CO 2 at 37°C. A total of 120 lung cancer patients and 45 controls (including 25 matched tumor and adjacent non-tumor samples) were recruited from the Southwest Hospital in Chongqing, China. This study was approved by the ethics committee of the Southwest Hospital. Informed consent was signed by all of the recruited patients.
DNA and RNA extraction DNA was extracted with a DNA Purification Wizard kit (Promega, Madison, WI, USA). Total RNAs were extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), and were treated with DNase I to eliminate the genomic DNA contamination. Then, complementary DNAs were synthesized using M-MLV First Strand Kit (Invitrogen), and stored at − 20°C.
Screening methylated fragments by MS-AP-PCR
DNA from the samples (mixture from 10 normal lung tissues or 20 lung cancer tissues) was separately digested by restriction enzyme. PCR was used to amplify the restriction digest DNA using a single primer MLG2 or a combination of two primers MGE2 and MGF2 that arbitrarily binds within GC-rich regions of DNA. Amplified products were purified, subcloned into vectors and sequenced. Sequence data were used to determine genomic information, using the NCBI's BLAST program (http://blast.ncbi.nlm.nih.gov).
Methylation analysis of SOX30 CpG islands by MSP and BGS
DNA samples were modified using the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA). The MSP and BGS were performed as previously reported. 38 Primers are listed in Supplementary Table S1 .
Mutation analysis
Five exons and promoter of SOX30 were amplified using genomic DNA with primers (Supplementary Table S1 ). The target fragments were purified, subcloned into vector and sequenced. Sequence homologies were analyzed using NCBI's BLAST.
Analysis of SOX30 expression by RT-PCR and qRT-PCR
The analysis of SOX30 mRNA expression levels was performed by RT-PCR and qRT-PCR. A series of PCRs with different cycle numbers were performed to determine the linear phase of amplification for RT-PCR. Based on these pilot experiments, the appropriate cycles were chosen. The qRT-PCR was performed using an iQ5 real-time detection system (Bio-Rad Laboratories, Hercules, CA, USA) and SYBR Premix Ex Taq II (Takara, Dalian, China). The relative expression levels were calculated using 2 − ΔΔct method. Primers are listed in Supplementary Table S1 .
De-methylation treatment with 5-aza-2′-deoxycytidine De-methylation experiments using 5-aza-2′-deoxycytidine were performed as previously described. 38 Tissue microarray All samples from lung cancer patients were reviewed histologically by hematoxylin and eosin staining, and two cores were taken from each representative tumor tissue and from lung tissue adjacent to the tumor within a distance of 10 μm to construct tissue microarray slides (in collaboration with the Shanghai Biochip Company Ltd, Shanghai, China). Duplicate cores from two different areas, intratumoral and peri-tumoral, were obtained. Then, tissue microarray sections with tumors and matched peri-tumoral samples were constructed. 39 Immunohistochemistry and WB analysis Immunohistochemical staining was performed using the antibody against SOX30 and Ki67 (1:100 or 1:50; Santa Cruz Biotechnology, Heidelberg, Germany) as described previously. 40 Fifty micrograms of protein was run on 10-15% sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Millipore Corporation, Bedford, MA, USA). After blocking with 5% milk for 2 h at room temperature, membranes was incubated overnight at 4°C with primary antibodies. After incubation with the secondary antibody, the proteins were detected by chemiluminescence (Pierce, Rockford, IL, USA). The same membrane was stripped and incubated with ACTIN monoclonal antibody (1:2000; Sigma), serving as an internal control. Primary antibodies were SOX30 rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology), p53 mouse polyclonal antibody (1:1000; Santa Cruz Biotechnology), BAX rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology), P21 rabbit polyclonal antibody (1:1000; Cell Signaling Technology, Boston, MA, USA) and PMAIP1 (NOXA) rabbit polyclonal antibody (1:1000; Santa Cruz Biotechnology). Secondary antibodies were horseradish peroxidase-conjugated donkey anti-rabbit and horseradish peroxidase-conjugated rabbit anti-mouse (1:3000, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA).
Construction of SOX30, miRNA expression vectors and cell transfection
The expression vector encoding full-length open reading frame of human SOX30 was constructed by synthesis and PCR amplification. Briefly, singlestranded oligonucleotides were designed and synthesized. The synthetic oligonucleotides were spliced into complete sequence by PCR, and validated by sequencing. Then, it was subcloned into the pIRES2-EGFP expression vector (Invitrogen Preservation, Carlsbad, CA, USA) and validated by sequencing. For knockdown, four pairs of oligomeric singlestranded oligonucleotides and a pair of negative oligomeric singlestranded oligonucleotides were synthesized, and then inserted into miRNA expression vector pcDNA6.2-GW/EmGFP-miR using the vector construction kit BLOCK-iT Pol II miR RNAi Expression Vector Kit with EmGFP (Invitrogen). The plasmids were transfected using ViaFect Transfection Reagent (Promega) or Lipofectamine2000 Reagent (Invitrogen). The stably transfected cells were screened under G418 (Calbiochem, La Jolla, CA, USA) or Blasticidin (Sigma). Cell clones were obtained by the cylinder method.
Colony formation assay A549 and H460 cells were plated in 12-well plates at 2 × 10 5 cells per well. For knockdown, A549-SOX30 stable cells were plated in 12-well plates at 3 × 10 5 cells per well. After culturing for 24 h, cells were transfected with SOX30 or vector control and miRNA or negative control, respectively. After 48 h of transfection, cells were collected, diluted 1:5, plated in 12-well plates and selected with 0.4 mg/ml of G418 or 4 μg/ml of Blasticidin for 14 days to establish stable clones in which the plasmids had stably integrated into genomic DNA. Surviving colonies (⩾50 cells per colony) were stained by using Giemsa's azur eosin methylene blue solution (Merck, Darmstadt, Germany) and counted. The experiment was carried out in triplicate wells for three times.
MTS and EdU assay
MTS and EdU assays were used to assess cell proliferation. A549 and H460 cells were plated at 3 × 10 3 cells per well on 96-well plates, and transfected with SOX30 or vector control. For knockdown, A549-SOX30 stable cells were plated at 3 × 10 3 cells per well on 96-well plates, and transfected with SOX30 miRNA or negative control. Cell proliferation was evaluated on days 1, 2, 3, 4 and 5 by determining the number of cells with Cell Proliferation Reagent MTS (Promega). The assay was carried out in triplicate for three independent experiments.
The effect of SOX30 suppression on cell proliferation was also tested by the EdU assay. Briefly, cells were cultured in 96-well plates and transfected with SOX30 or vector control for 46 h. Then, cells were incubated with 50 μm of EdU for additional 2 h at 37°C. Cells were fixed with 4% formaldehyde for 30 min, incubated with glycine (2 mg/ml) for 5 min and treated with 0.5% Triton X-100 for 10 min to permeabilize cells. After being washed with phosphate-buffered saline, cells were incubated with Apollo reaction cocktail for 30 min and treated twice with 0.5% Triton X-100. DNA was stained with Hoechst 33342 stain for 30 min and visualized with SOX30, methylation, apoptosis, p53 and lung cancerfluorescence microscopy. Five groups of confluent cells were randomly selected from each sample image.
Flow cytometry assay SOX30 or vector control-transfected cells (3 × 10 5 cells per well) were harvested at 48-h post-transfection, and fixed in 70% ethanol overnight at 4°C. The cells were stained with propidium iodide (BD Pharmingen, San Jose, CA, USA). A total of 30 000 cells were sorted by FACSCalibur System (BD Biosciences, Franklin Lakes, NJ, USA) and cell cycle profiles were analyzed using the ModFit software (Verity Software House, Topsham, ME, USA). Apoptosis was also determined by dual staining with Annexin V-APC/ 7-amino-actinomycin D (KeyGEN, Nanjing, China). Briefly, cells were harvested and washed with phosphate-buffered saline twice, and were resuspended in 500 μl binding buffer, 5 μl Annexin V-APC were added and mixed gently. Then, 5 μl 7-ADD were added, mixed gently and incubated for 5-15 min in the dark and 50 000 cells were analyzed using the FACSCalibur System. The relative proportion of Annexin V-positive cells was determined using the ModFit software and counted as apoptotic cells. The assays were carried out in triplicate for three times.
DNA ladder assay
Cells at 48-h post-transfection were harvested and resuspended in lysis buffer for 30 min on ice. After centrifugation, the supernatant was treated with RNase (100 μg/ml) for 30 min at 55°C and then with proteinase K (400 μg/ml) for another 1 h at 55°C. The cell lysates were extracted with phenol-chloroform. DNA was precipitated with ethanol, and electrophoresed on 1.5% agarose gels.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay
The apoptotic cells were detected in situ using the in situ cell death detection kit, POD (Roche, Penzberg, Germany). The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling method was performed according to the manufacturer's protocol. The sections after treatment were followed by incubation in diaminobenzidine substrate (Roche), and the reaction was observed under a microscope. Then, the nuclei were counterstained with hematoxylin buffer. The assay was carried out for three independent experiments.
In vivo tumorigenicity
To assess the effect of SOX30 expression on tumor formation in vivo, A549 and H460 cells with SOX30 or empty vector stably expression, for knockdown, A549-SOX30 stably cells with miRNA or negative control stably expression, were injected subcutaneously into the left and right flanks of 6-week-old male Balb/c nude mice, respectively. The tumor volume was calculated as 0.5236L1(L2) 2 , where L1 is the long axis and L2 is the short axis of the tumor. 41 The developing tumors were observed over the next 4 to 8 weeks, and the mice were then killed. All experiments on mice were approved by the Institutional Animal Care and Use Committee of Third Military Medical University, China.
Expression array analysis
Expression profiles were generated using Agilent 4 × 44 K expression arrays (Agilent, Mississauga, ON, USA). Total RNA was extracted, checked and purified by RNeasy mini kit (QIAGEN, GmBH, Hilden, Germany). After RNA amplification and labeling, each slide was hybridized with 1.65 μg labeled sample. Slides were washed in staining dishes after 17-h hybridization, and scanned using an Agilent Microarray Scanner (Agilent Technologies, Santa Clara, CA, USA). Data were extracted with the Feature Extraction software 10.7 (Agilent Technologies) and normalized by Quantile algorithm, Gene Spring Software 11.0 (Agilent Technologies). Genes with fold changes 4 or o 2.0 were considered to be of biological significance.
Site-directed mutagenesis of binding sites in p53 promoter and SOX30 HMG-box
The binding sites in the p53 promoter and SOX30 HMG-box constructs were mutated or deleted using a QuikChange Lightning Multi Site-Directed Mutagenesis Kit or a QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), and the mutations or deletions were confirmed by DNA sequencing.
Luciferase reporter assay
The cells were plated in 24-well plates (3-5 × 10 4 cells per well) in triplicate for each condition. After overnight incubation, cells were transfected with a DNA mix contained pGL3-p53 promoter-luciferase, pIRES2-EGFP-SOX30 or empty vector, and pRL-TK plasmids. Luciferase activities were measured 36-h post-transfection using a Dual-luciferase reporter kit (Promega). Each experiment was performed in triplicate and repeated three times.
ChIP assay
ChIP analysis was performed using a ChIP Assay Kit (Cell Signaling Technology). The immunoprecipitated and input DNA was used as a template for RT-PCR analysis using the primers listed in Supplementary Table S1 .
Statistical analysis
Statistical analyses were performed with the SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). The results are expressed as the mean ± s.d. Differences between two groups were analyzed using the Χ 2 test and the Student's ttest. The Mann-Whitney U-test was performed to compare the pathological variables of two sample groups in functional assay. Clinical and pathologic characteristics of the patients were compared by Pearson Χ 2 test or Fisher exact test. P-values o0.05 were taken as statistically significant.
